GBLT Receives a $4.7 million USD ($6.3 million CAD) Order for One of the Largest Drugstore Chains in Europe
TORONTO and DUREN, Germany, May 10, 2023 /CNW/ - GBLT Corp. (TSXV: GBLT) ("GBLT" or the "Company") is pleased to announce that the Company has received a large new order for one of the largest European drugstore chains for a minimum expected volume of $4.7 million USD ($6.3 million CAD) to provide battery products this year.
"We are pleased to continue our long-term relationship with one of the largest drugstore retailers in Europe as they continue to provide consistent sales commitments as we continue to provide quality products," said Dr. Thilo Senst, CEO of GBLT. "Batteries have been our entry product to many of our retailers which has led to introducing different products from the diverse product offerings GBLT has to offer. We continue to focus on scaling all our operations in major markets in Europe and beyond and are pleased to continue to provide to our longest and most loyal customers as well as increasing product sales in new customers and territories."
Dr. Senst continued, "We are expanding and scaling our products this year at a very fast rate, and we continue to foster our long-term relationships with large stable retailers and distributors as they continue to provide reliable and large sales orders necessary for our company's bottom line growth. With the expansion of our product offerings this year ranging from full service solar energy products to personal healthcare lines we plan to continue to grow our presence in the European market and beyond."
* |
Exchange rate 1.34 CAD/USD (2023-05-08) as per https://www.bankofcanada.ca/rates/exchange/daily-exchange-rates/ |
GBLT Corp., through its operating company, GBT GmbH, designs, manufactures and supplies mobile storage, and battery solutions. GBLT is also a leading provider of renewable energy solutions via its solar division, participating in the rapidly growing solar energy market. In addition, the Company offers consumer healthcare and wellness products to some of the largest retail chains across the globe. GBT is also an official licensee for AGFAPHOTO mobile energy products. The Company's branded healthcare and wellbeing products are primarily sold throughout Europe under Dr. Senst brand.
For more information, please visit www.gbt-international.com and www.gbltcorp.com.
Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement, the Company's ability to achieve sales, commercial or otherwise, from its products, and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE GBLT Corp.
GBLT Corp.: Dr. Thilo Senst, CEO, Tel.: +49(0)2421-20856-0, Email: [email protected]; Investor Relations: Virtus Advisory Group, Tel: 416-646-6779, Email : [email protected]
Share this article